Proliferation Determined by Ki-67 Defines Different Pathologic Response to Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer

Clinical Breast Cancer

Volumn 15, Issue 5, 2015, Pages 343-347

  Sánchez Muñoz, Alfonso ^a   Navarro Perez, Victor ^a   Plata Fernández, Yessica ^b   Santonja, Angela ^a   Moreno, Ignacio ^a   Ribelles, Nuria ^a   Alba, Emilio ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b Medical Oncology Service   (Spain)

Author keywords

HER2 positive breast cancer; Ki 67 marker; Neoadjuvant trastuzumab based chemotherapy; Pathologic complete response; Predictive factor

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; KI 67 ANTIGEN; PACLITAXEL; TRASTUZUMAB; TUMOR MARKER; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CELL PROLIFERATION; DISEASE FREE SURVIVAL; DRUG RESPONSE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RECURRENT DISEASE; ADJUVANT CHEMORADIOTHERAPY; BREAST NEOPLASMS; CANCER STAGING; METABOLISM; NEOADJUVANT THERAPY; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMORADIOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; KI-67 ANTIGEN; NEOADJUVANT THERAPY; NEOPLASM STAGING; PACLITAXEL; RECEPTOR, ERBB-2; TRASTUZUMAB;

EID: 84941317519     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2015.01.005     Document Type: Article

References (22)

1. D.J. Slamon, G.M. Clark, S.G. Wong, and et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
2. M. Untch, P.A. Fasching, G.E. Konecny, and et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups J Clin Oncol 29 2011 3351 3357
3. L. Gianni, W. Eiermann, V. Semiglazov, and et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort Lancet 375 2010 377 384
4. M. Untch, M. Rezai, S. Loibl, and et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study J Clin Oncol 28 2010 2024 2031
5. V. Guarneri, K. Broglio, S.W. Kau, and et al. Prognostic value of pCR after primary chemotherapy in relation to hormone receptor status and other factors J Clin Oncol 24 2006 1037 1044
6. A. Sánchez-Muñoz, A.M. García-Tapiador, E. Martínez-Ortega, and et al. Tumour molecular subtyping according to hormone receptors and HER2 status defines different pCR to neoadjuvant chemotherapy in patients with locally advanced breast cancer Clin Transl Oncol 10 2008 646 653
7. J. Chang, M. Ormerod, T.J. Powles, and et al. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma Cancer 89 2000 2145 2152
8. I.F. Faneyte, J.G. Schrama, J.L. Peterse, and et al. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome Br J Cancer 88 2003 406 412
9. V. Guarneri, A. Frassoldati, A. Bottini, and et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study J Clin Oncol 30 2012 1989 1995
10. J. Baselga, I. Bradbury, H. Eidtmann, and et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet 379 2012 633 640
11. L. Gianni, T. Pienkowski, Y.H. Im, and et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet Oncol 13 2012 25 32
12. M. Untch, R.D. Gelber, C. Jackisch, and et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial Ann Oncol 19 2008 1090 1096
13. R. Stuart-Harris, C. Caldas, S.E. Pinder, and P. Pharoah Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients Breast 17 2008 323 334
14. E. de Azambuja, F. Cardoso, G. de Castro Jr., and et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients Br J Cancer 96 2007 1504 1513
15. A. Urruticoechea, I.E. Smith, and M. Dowsett Proliferation marker Ki-67 in early breast cancer J Clin Oncol 23 2005 7212 7220
16. P. Wirapati, C. Sotiriou, S. Kunkel, and et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures Breast Cancer Res 10 2008 R65
17. A.G. Rivenbark, S.M. O'Connor, and W.B. Coleman Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine Am J Pathol 183 2013 1113 1124
18. J.C. Harrell, A. Prat, J.S. Parker, and et al. Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse Breast Cancer Res Treat 132 2012 523 535
19. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours Nature 490 2012 61 70
20. A. Prat, G. Bianchini, M. Thomas, and et al. Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study Clin Cancer Res 20 2014 511 521
21. G.C. Zhang, X.K. Qian, Z.B. Guo, and et al. Pre-treatment hormonal receptor status and Ki-67 index predict pCR to neoadjuvant trastuzumab/taxanes but not disease-free survival in HER2-positive breast cancer patients Med Oncol 29 2012 3222 3231
22. G. Von Minckwitz, M. Untch, J.U. Blohmer, and et al. Definition and impact of pCR on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes J Clin Oncol 30 2012 1796 1804